Neon Therapeutics launched its immunotherapy platform with $55m in Series A venture capital, exceeding recent investments in several other private therapeutics companies, including a diabetes drug developer on its fifth round of funding.
Neon's focus on the hot cancer immunotherapy field rose to the top in a recent spate of VC fundraising announcements, but Elcelyx Therapeutics disclosed a still impressive $40m Series E round to fund its Phase IIb clinical trial for metformin delayed-release (metformin DR)
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?
